Loading clinical trials...
Loading clinical trials...
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma
Conditions
Interventions
HDP-101
Locations
16
United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Mount Sinai, The Tisch Cancer Instutute
New York, New York, United States
MD Anderson Cancer Center
Houston, Texas, United States
Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie
Berlin, Germany
Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III
Chemnitz, Germany
Universitätsklinikum Köln
Cologne, Germany
Start Date
February 7, 2022
Primary Completion Date
August 1, 2025
Completion Date
May 1, 2026
Last Updated
July 24, 2024
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Heidelberg Pharma AG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions